No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good perfor...
Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed i...
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with meta...
3566 Background: In a phase III pivotal trial in pts with mCRC, BV (Avastin) increased overall survival when added to first-line irinotecan, fluorouracil, and leucovorin. Safety...
h-index: Number of publications with at least h citations each.